BlossomHill Therapeutics gets FDA Fast Track for BH-30643 in EGFR C797S+ NSCLC
BlossomHill Therapeutics announces the FDA grants Fast Track designation to BH-30643, its macrocyclic OMNI-EGFR™ inhibitor, for treating advanced EGFR C797S-positive NSCLC.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.